Luseogliflozin (TS 071) is a potent, selective, orally activesodium-dependent glucose cotransporter (SGLT) 2inhibitor, with anIC₅₀of 2.26 nM, about 1765-fold selectivity overSGLT1(IC₅₀, 3990 nM). Luseogliflozin has the protential for treating type 2 diabetes.

Luseogliflozin (TS-071, 3p) is a potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor, with an IC₅₀of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC₅₀, 3990 nM); Luseogliflozin has the protential for treating type 2 diabetes^[1].

Luseogliflozin (1 mg/kg, p.o.) exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in rats and dogs^[1].

434.55

C₂₃H₃₀O₆S

898537-18-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.